Bausch Health Companies I... (BHC)
Bid | 4.34 |
Market Cap | 1.61B |
Revenue (ttm) | 9.61B |
Net Income (ttm) | -45.71M |
EPS (ttm) | -0.13 |
PE Ratio (ttm) | -33.42 |
Forward PE | 1.72 |
Analyst | Hold |
Ask | 4.35 |
Volume | 905,498 |
Avg. Volume (20D) | 2,954,130.9 |
Open | 4.46 |
Previous Close | 4.32 |
Day's Range | 4.33 - 4.50 |
52-Week Range | 3.96 - 9.85 |
Beta | 0.43 |
About BHC
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on...
Analyst Forecast
According to 5 analyst ratings, the average rating for BHC stock is "Hold." The 12-month stock price forecast is $8, which is an increase of 84.12% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription

4 days ago · accessnewswire.com
Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship ProgramBausch Health is offering scholarships to six students impacted by dermatologic conditions, with application submissions open through June 11, 2025 LAVAL, QC / ACCESS Newswire / April 10, 2025 / Bausc...

2 weeks ago · accessnewswire.com
Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured NotesLAVAL, QC / ACCESS Newswire / March 25, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has priced its previously announced offering ...